



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Linie	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
							AMG-Studien				
Mamma-Ca		x				CAMBRIA-1 EudraCT Number 2022-501024-20-00	A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence	x			
Mamma-Ca	x					ADAPT-HER2-IV EudraCT Number	NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus paclitaxel+/-carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer		x	x	
Mamma-Ca				x	1	pionERA CO44657 EudraCT Number	A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT , BOTH COMBINED WITH A CDK4/6 INHIBITOR , IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY	x			
Mamma-Ca	x	x				TROPION Breast04 EudraCT Number 2023-505928-59-00	A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)				x
Mamma-Ca		x				ADAPTlate EudraCT Number 2019-001488-60	A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+/HER2- early breast cancer	x			
	Primär			Metastasiert							

Ovar-Ca	x				AGO-OVAR 28 / ENGOT-ov57 EudraCT Number 2021-001271-16	Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Protocol-code: AGO-OVAR 28 / ENGOT-ov57)				
						Sonstige Studien				
Mamma- Ca und Schwangerschaft					GBG 29 BCP	Prospektive Registerstudie zur Diagnostik und Therapie des Mamma-karzinoms in der Schwangerschaft Pat. mit histologisch gesichertem Mammakarzinom und Schwangerschaft	x	x	x	x
Mamma-Ca				x	GBG79 BrainMet	Brain Metastases in Breast Cancer Network Germany (BMBC) Meeting a clinical need for the improvement of patient outcome	x	x	x	x
Mamma-Ca beim Mann					Register Magdeburg	Mammakarzinom des Mannes. Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit den klinischen Krebsregistern zur Diagnostik und Therapie des Mammakarzinoms des Mannes	x	x	x	x
alle gyn. Tumorpatienten					Psychonkologische Studie von ONKOTRAKT	Epidemiologische Untersuchung zur Belastung von Krebspatienten (Verbesserung der Erkennung des psychoonkologischen Betreuungsbedarfs bei Krebskranken)				